LIVZON PHARMA announced its financial results for the first quarter of 2026. The company reported revenue of 2.871 billion yuan, a decrease of 9.73% compared to the same period last year. Net profit attributable to shareholders was 577 million yuan, declining by 9.39% year-on-year.
The fluctuation in revenue was attributed to the transitional phase of industry policy adjustments and seasonal variations in the incidence of influenza and respiratory infections during the quarter. Despite these challenges, the company's overall operations remained stable, with the core business maintaining strong operational quality.
Specific factors contributing to the revenue adjustment include a lower incidence rate of domestic influenza and respiratory diseases in Q1 2026 compared to Q1 2025, leading to a corresponding decrease in revenue from antiviral granules and respiratory-related diagnostic products. Additionally, the implementation of the eleventh round of centralized drug procurement policy has resulted in a transitional period for price adjustments of certain included products, temporarily impacting revenue. The active pharmaceutical ingredients segment also experienced seasonal fluctuations in customer orders.
In response, the company has actively implemented measures to enhance operational resilience and risk resistance. These include cost optimization, improved operational efficiency, customer structure refinement, and accelerated commercialization of innovative products.
Key strategic focuses include the rapid market expansion of core innovative products such as Aripiprazole Microspheres for Injection and Triptorelin Acetate Microspheres for Injection, which have been included in the national reimbursement drug list and are entering a phase of rapid sales growth. The innovative drug sector is expected to become a new engine for performance growth.
Furthermore, the company's R&D pipeline continues to deliver, with key products in late-stage development or registration phases—such as Laikoncitumab, JP-1366 tablets, and recombinant human follicle-stimulating hormone—progressing toward commercialization, providing solid support for medium-to-long-term development.
International expansion efforts are also advancing, with the acquisition project in Vietnam proceeding as planned and international registration processes accelerating, opening up potential new growth opportunities.